Disclosing payments from pharma companies

Securing on-line credit card payments without disclosing privacy information

Two revisions of the original Secure Electronic Transaction (SET) protocol are proposed to conceal cardholders’ identities in the electronic marketplace in which cardholders’ trust for banks can be reduced to a minimum. Constrained by being extensions of the existing card payment networks to the Internet, most on-line credit card payment schemes in use or proposed in recent papers assume the se...

Good pharma? Bad pharma? Better pharma.

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study

BACKGROUND Financial relationships between physicians and industry are extensive and public reporting of industry payments to physicians is now occurring. Our objectives were to describe physician recipients of large total payments from these seven companies, and to examine discrepancies between these payments and conflict of interest (COI) disclosures in authors' concurrent publications. MET...

Making sense of a complex world Revenue recognition : payments to customers – issues for media companies

This paper explores some of the key IFRS accounting considerations for payments by media companies to their customers.

Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.

INTRODUCTION Imagine that CureCo, Inc., is the exclusive seller of a patented product that yields hundreds of millions of dollars per year in revenues. CopyCo International announces its intention to market the product and compete with CureCo. CureCo promptly sues CopyCo for patent infringement. A federal court holds that the patent is invalid, appearing to clear the way for CopyCo to enter the...